252758-93-3

Basic information

• Product Name: 2-(3-METHYL-PIPERIDIN-1-YL)-PHENYLAMINE
• Synonyms: TIMTEC-BB SBB007134;AKOS BC-2603;AKOS B021946;2-(3-METHYL-PIPERIDIN-1-YL)-PHENYLAMINE;ART-CHEM-BB B021946;2-(3-METHYLPIPERIDIN-1-YL)BENZENAMINE
• CAS NO: 252758-93-3
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Mol File: 252758-93-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(3-METHYL-PIPERIDIN-1-YL)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-METHYL-PIPERIDIN-1-YL)-PHENYLAMINE(252758-93-3)
• EPA Substance Registry System: 2-(3-METHYL-PIPERIDIN-1-YL)-PHENYLAMINE(252758-93-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 252758-93-3(Hazardous Substances Data)

Usage

Derivative of phenylamine

It is a compound derived from phenylamine This means that 2-(3-methyl-piperidin-1-yl)-phenylamine is structurally related to phenylamine, with modifications to its chemical structure.

Substituted piperidine group

It contains a piperidine group with a methyl substitution This refers to the presence of a five-membered nitrogen-containing ring (piperidine) with one of its carbon atoms having a methyl group (CH3) attached.

Potential pharmaceutical applications

It has potential applications in the pharmaceutical industry This means that 2-(3-methyl-piperidin-1-yl)-phenylamine could be used in the development of new drugs for treating various medical conditions.

Varying properties and uses

The specific properties and uses may vary depending on the intended application and the specific chemical properties of the compound This indicates that the compound's effectiveness and utility will depend on its specific chemical characteristics and the particular purpose for which it is being used.

Need for further research and testing

Further research and testing are likely needed to fully understand and harness the potential of this chemical This highlights the importance of additional studies to explore the compound's properties and potential applications more thoroughly.

Upstream product

• 88-73-3 2-Chloronitrobenzene 
• 78019-76-8 3-methyl-1-(2-nitrophenyl)-piperidine 

Relevant articles and documents

Synthesis, antifungal activity and QSAR of some novel carboxylic acid amides

A series of novel aromatic carboxylic acid amides were synthesized and tested for their activities against six phytopathogenic fungi by an in vitro mycelia growth inhibition assay. Most of them displayed moderate to good activity. Among them N-(2-(1H-indazol-1-yl)phenyl)-2-(trifluoromethyl)benzamide (3c) exhibited the highest antifungal activity against Pythium aphanidermatum (EC50 = 16.75 μg/mL) and Rhizoctonia solani (EC50 = 19.19 μg/mL), compared to the reference compound boscalid with EC50 values of 10.68 and 14.47 μg/mL, respectively. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were employed to develop a three-dimensional quantitative structure-activity relationship model for the activity of the compounds. In the molecular docking, a fluorine atom and the carbonyl oxygen atom of 3c formed hydrogen bonds toward the hydroxyl hydrogens of TYR58 and TRP173.

Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents

A series of 2′-aminoanilides have been identified which exhibit potent and selective inhibitory activity against the cFMS tyrosine kinase. Initial SAR studies within this series are described which examine aroyl and amino group substitutions, as well as the introduction of hydrophilic substituents on the benzene core. Compound 47 inhibits the isolated enzyme (IC50 = 0.027 μM) and blocks CSF-1-induced proliferation of bone marrow-derived macrophages (IC50 = 0.11 μM) and as such, serves as a lead candidate for further optimization studies.

Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors

Compounds of formula (I) or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP1B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.